Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $19.01 USD
Change Today -0.38 / -1.96%
Volume 71.0K
As of 8:04 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Barry D. Quart Pharm.D.

Former General Manager of Americas Region, Kodak's Business Solutions and Services, Eastman Kodak Co.
AgeTotal Calculated CompensationThis person is connected to 27 board members in 4 different organizations across 7 different industries.

See Board Relationships
57$3,884,259

Background*

Dr. Barry D. Quart, Pharm.D., has been the Chief Executive Officer of Heron Therapeutics, Inc. (Alternate Name, AP Pharma Inc.) since May 2, 2013. Dr. Quart serves as the Scientific Advisor of Napo Pharmaceuticals, Inc. He served as the Chief Executive Officer and President of Ardea Biosciences, Inc. since December 21, 2006, which was acquired by AstraZeneca PLC in June 2012. He served as General Manager for Americas Region, Kodak's Business Solutions and Services of ...

Read Full Background

Corporate Headquarters*

343 State Street
Rochester, New York 14650

United States

Phone: 585-724-4000
Fax: --

Board Members Memberships*

Director
2002-2006
Scientific Advisor
2006-N/A
Former Chief Executive Officer, President and Executive Director
2006-Present
Director
2007-Present
Director
2007-N/A
Director, Member of Audit Committee and Member of Compensation Committee
2012-Present
Chief Executive Officer and Director

Education*

Doctorate
University of California-San Francisco

Other Affiliations*

Annual Compensation*

Salary$540,750
Total Annual Compensation$540,750

Stock Options*

All Other Compensation$7,800
Exercisable Options141,067
Exercisable Options Value$240,997
Unexercisable Options1,307,690
Unexercisable Options Value$2,995,369
Total Value of Options$3,236,365
Total Number of Options1,448,757

Total Compensation*

Total Annual Cash Compensation$801,351
Total Short Term Compensation$540,750
Other Long Term Compensation$7,800
Total Calculated Compensation$3,884,259
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KODK:US $19.01 USD -0.38

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Richard F. Pops Chairman of the Board and Chief Executive Officer
Alkermes plc
$854.7K
David M. Stack Chairman, Chief Executive Officer and President
Pacira Pharmaceuticals, Inc.
$1.0M
Alex Gorsky Chairman, Chief Executive Officer, Chairman of Executive Committee and Chairman of Finance Committee
Johnson & Johnson
$1.5M
Olivier Brandicourt Chief Executive Officer and Director
Sanofi
--
Dov Tamarkin Ph.D.Co-Founder, Chief Executive Officer and Director
Foamix Pharmaceuticals Ltd.
$320.3K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EASTMAN KODAK CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.